| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/25/2023 | 82.93% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 09/21/2023 | 82.93% | Maxim Group | → $6 | Initiates Coverage On | → Buy |
| 09/18/2023 | 82.93% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 05/18/2023 | 143.9% | Benchmark | → $8 | Reiterates | Speculative Buy → Speculative Buy |
| 02/14/2023 | 143.9% | Benchmark | $10 → $8 | Maintains | Speculative Buy |
| 07/27/2022 | 82.93% | Ladenburg Thalmann | → $6 | Initiates Coverage On | → Buy |
| 05/25/2021 | 357.32% | Benchmark | → $15 | Initiates Coverage On | → Buy |
What is the target price for Anebulo Pharmaceuticals (ANEB)?
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by HC Wainwright & Co. on September 25, 2023. The analyst firm set a price target for $6.00 expecting ANEB to rise to within 12 months (a possible 82.93% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by HC Wainwright & Co., and Anebulo Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.
Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a reiterated with a price target of $0.00 to $6.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $3.28, which is within the analyst's predicted range.